40 related articles for article (PubMed ID: 38568057)
21. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract][Full Text] [Related]
22. Alternative approaches to target Myc for cancer treatment.
Wang C; Zhang J; Yin J; Gan Y; Xu S; Gu Y; Huang W
Signal Transduct Target Ther; 2021 Mar; 6(1):117. PubMed ID: 33692331
[TBL] [Abstract][Full Text] [Related]
23. MYC as a target for cancer treatment.
Duffy MJ; O'Grady S; Tang M; Crown J
Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
[TBL] [Abstract][Full Text] [Related]
24. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc.
Madden SK; de Araujo AD; Gerhardt M; Fairlie DP; Mason JM
Mol Cancer; 2021 Jan; 20(1):3. PubMed ID: 33397405
[TBL] [Abstract][Full Text] [Related]
25. C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors.
Ashrafizadeh M; Zarabi A; Hushmandi K; Moghadam ER; Hashemi F; Daneshi S; Hashemi F; Tavakol S; Mohammadinejad R; Najafi M; Dudha N; Garg M
Curr Cancer Drug Targets; 2021; 21(1):2-20. PubMed ID: 33069197
[TBL] [Abstract][Full Text] [Related]
26. The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells.
AlSultan D; Kavanagh E; O'Grady S; Eustace AJ; Castell A; Larsson LG; Crown J; Madden SF; Duffy MJ
Invest New Drugs; 2021 Apr; 39(2):587-594. PubMed ID: 33052557
[TBL] [Abstract][Full Text] [Related]
27. Development of Small Molecule MEIS Inhibitors that modulate HSC activity.
Turan RD; Albayrak E; Uslu M; Siyah P; Alyazici LY; Kalkan BM; Aslan GS; Yucel D; Aksoz M; Tuysuz EC; Meric N; Durdagi S; Gulbas Z; Kocabas F
Sci Rep; 2020 May; 10(1):7994. PubMed ID: 32409701
[TBL] [Abstract][Full Text] [Related]
28. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.
Han H; Jain AD; Truica MI; Izquierdo-Ferrer J; Anker JF; Lysy B; Sagar V; Luan Y; Chalmers ZR; Unno K; Mok H; Vatapalli R; Yoo YA; Rodriguez Y; Kandela I; Parker JB; Chakravarti D; Mishra RK; Schiltz GE; Abdulkadir SA
Cancer Cell; 2019 Nov; 36(5):483-497.e15. PubMed ID: 31679823
[TBL] [Abstract][Full Text] [Related]
29. c-Myc Inhibitor 10074-G5 Induces Murine and Human Hematopoietic Stem and Progenitor Cell Expansion and HDR Modulator Rad51 Expression.
Aksoz M; Albayrak E; Aslan GS; Turan RD; Alyazici LY; Siyah P; Tuysuz EC; Canikyan S; Yucel D; Meric N; Gulbas Z; Sahin F; Kocabas F
Curr Cancer Drug Targets; 2019; 19(6):479-494. PubMed ID: 30182856
[TBL] [Abstract][Full Text] [Related]
30. Smart Drug Delivery Systems in Cancer Therapy.
Unsoy G; Gunduz U
Curr Drug Targets; 2018 Feb; 19(3):202-212. PubMed ID: 27033191
[TBL] [Abstract][Full Text] [Related]
31. Pharmacophore identification of c-Myc inhibitor 10074-G5.
Yap JL; Wang H; Hu A; Chauhan J; Jung KY; Gharavi RB; Prochownik EV; Fletcher S
Bioorg Med Chem Lett; 2013 Jan; 23(1):370-4. PubMed ID: 23177256
[TBL] [Abstract][Full Text] [Related]
32. Deciphering the intricate regulatory mechanisms for the cellular choice between cell repair, apoptosis or senescence in response to damaging signals.
Erol A
Cell Signal; 2011 Jul; 23(7):1076-81. PubMed ID: 21144894
[TBL] [Abstract][Full Text] [Related]
33. Improved low molecular weight Myc-Max inhibitors.
Wang H; Hammoudeh DI; Follis AV; Reese BE; Lazo JS; Metallo SJ; Prochownik EV
Mol Cancer Ther; 2007 Sep; 6(9):2399-408. PubMed ID: 17876039
[TBL] [Abstract][Full Text] [Related]
34. c-myc and bcl-2 Expression in supraglottic squamous cell carcinoma of the larynx.
Ozdek A; Sarac S; Akyol MU; Sungur A; Yilmaz T
Otolaryngol Head Neck Surg; 2004 Jul; 131(1):77-83. PubMed ID: 15243561
[TBL] [Abstract][Full Text] [Related]
35. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
36. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
37. Development, synthesis and validation of improved c-Myc/Max inhibitors.
Yıldırım S; Kocabaş F; Mermer A
J Cell Mol Med; 2024 Apr; 28(8):e18272. PubMed ID: 38568057
[TBL] [Abstract][Full Text] [Related]
38. MYC the oncogene from hell: Novel opportunities for cancer therapy.
Papadimitropoulou A; Makri M; Zoidis G
Eur J Med Chem; 2024 Mar; 267():116194. PubMed ID: 38340508
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
